October 2024 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
3 citations
,
February 2022 in “Rheumatology” Baricitinib was effective in treating a patient with dermatomyositis and hair loss.
April 2024 in “Expert opinion on emerging drugs” New treatments for male hair loss are being explored to improve effectiveness and reduce side effects.
3 citations
,
July 2024 in “Archives of Dermatological Research” Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
September 2015 in “Journal watch” Triamcinolone acetonide injections help regrow hair in alopecia areata patients.
19 citations
,
April 2020 in “Dermatologic Therapy” Dutasteride works better than finasteride for hair loss, with both being safe to use.
12 citations
,
May 2023 in “EMBO reports” High mTORC1 activity slows hair growth and causes it to lose color.
April 2023 in “Journal of the American Academy of Dermatology” Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
December 2012 in “http://isrctn.org/>”
September 2025 in “Arthritis Research & Therapy” BMS-470539 reduces skin fibrosis and inflammation.
1 citations
,
July 2024 in “Journal of the European Academy of Dermatology and Venereology” Oral dutasteride is effective and safe for treating frontal fibrosing alopecia.
March 2014 in “Journal of The American Academy of Dermatology” Tavaborole is a safe and effective toenail fungus treatment, with the 5% solution being the best option.
November 2023 in “Journal of Cosmetic Dermatology” Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
June 2014 in “Dermatology Times E-News” An arthritis drug helped a person with severe hair loss regrow their hair.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib works better in adolescents than adults for treating severe alopecia areata.
January 2025 in “Geneesmiddelenbulletin” Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.
7 citations
,
August 2006 in “Maturitas” Cimicifuga racemosa extract may help prevent and treat prostate issues by inhibiting 5α-reductase.
2 citations
,
August 2019 in “PubMed” A specific enzyme that activates the hair growth medication minoxidil when applied to the skin was identified.
3 citations
,
January 2016 in “Case reports in dermatological medicine” An 80-year-old man grew extra hair on his forearms after starting Alzheimer's medication rivastigmine.
1 citations
,
January 2024 in “Arab Board Medical Journal” Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.
45 citations
,
January 1981 in “Annals of Internal Medicine” Minoxidil controls blood pressure effectively, but may cause side effects like hypertrichosis.
June 2026 in “Eurasian Journal of Medicine” April 2026 in “Benha Medical Journal”
19 citations
,
September 2014 in “British Journal of Dermatology” Minoxidil foam 5% effectively treats hair loss in both frontal and vertex scalp regions.
16 citations
,
January 2017 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)” A patient with complete hair loss regrew all her hair using tofacitinib.
June 2024 in “Korean Journal of Pharmacognosy” The compound from Rhododendron mucronulatum roots may help treat male pattern hair loss.
July 2025 in “Saudi Journal of Medicine and Public Health” 5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.
August 2016 in “Journal of Investigative Dermatology” Blocking the CCR5 receptor may be a new way to treat hair loss from alopecia areata.
May 2024 in “Reactions weekly” 44 citations
,
January 1997 in “British Journal of Dermatology” Stopping 5% topical minoxidil can reverse unwanted hair growth on the face and limbs.